DCOY · Decoy Therapeutics Inc. · Investor Relations
$1.66
-0.11 (-6.21%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The lack of revenue from product sales to date and recurring losses from operations since its inception raise substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.29M
Shares
655,185
Volume · Oct 5
108.03K
Avg daily vol (3M)
2.16M
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-03 | Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform | Event |
| 2026-07-27 | Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats | Event |
| 2026-07-15 | Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors | Shareholder meeting |
| 2026-06-26 | Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing | Event |
| 2026-06-22 | June 2026 Corporate Investor Presentation Available | Presentation |
| 2026-06-11 | HVIVO CAPITAL MARKETS DAY | Presentation |
| 2026-06-08 | Decoy Therapeutics’ CEO to Participate in hVIVO Capital Markets Day in London | Presentation |
| 2026-04-09 | VIRTUAL INVESTOR CLOSING BELL EVENT (LIVE) | Event |
| 2026-02-10 | CORPORATE CONNECT WEBINAR SERIES | Event |
Source: https://investors.decoytx.com/